The role of the liver in the development of atherosclerosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This paper reviews current understanding based on the latest comprehensive global research on the multi-component etiology and pathogenesis of atherosclerosis, including the role of the liver, modern diagnostic criteria, and patient management strategies for this condition, taking into account new data.

About the authors

Evgeniya N. Zinovieva

LLC «Medi Prof» «SM-Clinic» on Dunaysky Prospekt

Author for correspondence.
Email: enzinovyeva@mail.ru
ORCID iD: 0000-0001-7859-7124

Candidate of Medical Sciences, Associate Professor, Expert Gastroenterologist

Russian Federation, Saint Petersburg

References

  1. Feingold K.R. Introduction to Lipids and Lipoproteins [Updated 2021 Jan 19]. In: Feingold K.R., Anawalt B., Blackman M.R. et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc., 2000.
  2. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. под ред. И.Е. Чазовой. Практическая медицина. 2010; 5 (44): 81–101. [Expert Recommendations of the All-Russian Scientific Society of Cardiologists on the Diagnosis and Treatment of Metabolic Syndrome. Second Revision. Edited by I.E. Chazova. Practical Medicine. 2010; 5 (44): 81–101].
  3. Targher G., Bertolini L., Padovani R. et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care. 2004; 27: 2498–2500.
  4. Brea A., Mosquera D., Martín E. et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005; 25: 1045–1050.
  5. Targher G., Bertolini L., Padovani R. et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006; 29: 1325–1330.
  6. Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intimamedia thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204: 521–525.
  7. S. Ramilli S., Pretolani A. Muscari et al. Carotid lesions in outpatients with nonalcoholic fatty liver disease Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol. 2009; 15 (38): 4770–4774.
  8. Chung G.E., Choi S.-Y., Kim D. et al. Nonalcoholic Fatty Liver Disease as a Risk Factor of Arterial Stiffness Measured by the Cardioankle Vascular Index. Medicine (Baltimore). 2015; 94 (12): 654. DOI: 0.1097/MD.0000000000000654.
  9. Li N., Zhang G.W., Zhang J.R. et al. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis. 2015; 25 (2): 218–223. doi: 10.1016/j.numecd.2014.10.002
  10. Wang C.C., Lin S.K., Tseng Y.F. et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009; 24 (8): 1411–1416. doi: 10.1111/j.1440-1746.2009.05872.
  11. Kim K.S., Oh H.J., Kim D.J. et al. The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels. Endocr J. 2013; 60 (12): 1295–1301.
  12. Pais R., Giral Ph., Khan J.-F. et al. Fatty liver disease is an independent prognostic factor for early atherosclerosis of the carotid arteries.Journal of Hepatology. 2016; 65: 95–102.
  13. Mahfood Haddad T., Hamdex S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver dis ease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2017; 11 (S1): S209–S216. doi: 10.1016/j.dsx.2016.12.033.
  14. Patel N.S., Doycheva I., Peterson M.R. et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13 (3): 561–58.
  15. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines, on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81 (3): 492–542.
  16. Mantovani A., Byrne C.D., Scorletti E. et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab. 2020; 46 (6): 427–441.
  17. Liu Y., Wei R., Hong T.P. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20 (27): 9090–9097.
  18. Sattar N., Fitchett D., Hantel S. et al. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia. 2018; 61 (10): 2155–2163.
  19. Belfort R., Harrison S.A., Brown K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355 (22): 2297–2307.
  20. Deng X.L., Ma R., Zhu H.X. et al. Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2017; 29 (3): 297–301.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Russkiy Vrach Publishing House